Form 4: Alnylam Pharmaceuticals Director Colleen F. Reitan Reports Transactions in Company Stock

Director Colleen F. Reitan reports acquisition and disposal of Alnylam Pharmaceuticals stock and stock options.

Summary

• On August 29, 2024, Colleen F. Reitan acquired 32 shares of Alnylam Pharmaceuticals common stock at $286 per share.
• On October 17, 2024, she acquired 4 shares at $302.67 per share.
• On April 16, 2025, she disposed of 36 shares at $232.86 per share.
• On May 8, 2025, she acquired 775 shares represented by restricted stock units (RSUs) under the 2018 Stock Incentive Plan, vesting upon the earlier of the first anniversary of the grant date or retirement/resignation within 90 days prior to the anniversary.
• On May 8, 2025, she also acquired a stock option to buy 1,558 shares at $258.35, vesting under the same conditions as the RSUs, expiring on May 8, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are a mix of acquisitions and disposals, with no clear indication of strong positive or negative sentiment from the director's actions. The acquisition of RSUs and stock options is mildly positive, but the disposal of shares tempers this.

Positives

• The acquisition of RSUs and stock options could be seen as a positive sign, indicating the director's confidence in the company's future performance.

Negatives

• The disposal of 36 shares on April 16, 2025, could be interpreted negatively, although the quantity is small.

Risks

• The vesting of RSUs and stock options is contingent upon continued service or retirement/resignation within a specific timeframe, which introduces a dependency on the director's continued involvement with the company.

Future Outlook

The vesting of RSUs and stock options is contingent upon the director's continued service or retirement/resignation within a specific timeframe.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities, which can be informative for investors.

Comparison to Industry Standards

• Comparing the director's trading activity to that of other executives in similar pharmaceutical companies could provide insights into the relative valuation and prospects of Alnylam.
• Benchmarking the vesting terms of the RSUs and stock options against industry standards can reveal whether the incentives are aligned with long-term shareholder value creation.

Stakeholder Impact

• The reported transactions may influence investor sentiment and potentially impact the stock price.

Key Dates

Keywords

Alnylam Pharmaceuticals, Director, Stock Transactions, RSUs, Stock Options, Beneficial Ownership, Form 4